Gilead posts quarterly loss, revenue rises 5%

(Reuters) - Gilead Sciences reported a first-quarter loss on Thursday after taking a $3.9 billion charge for its recent acquisition of liver drug developer CymaBay Therapeutics, while revenue rose 5%